Fosun Highlights Innovation at CIIE
On November 5, the China International Import Expo (CIIE) commenced at the National Exhibition and Convention Center, welcoming a host of global exhibitors. Fosun, a prominent participant for eight consecutive years, unveiled its impressive portfolio at the event, particularly in the areas of medical devices and innovative pharmaceuticals. This year, the Fosun Pharma booth showcased advancements in oncology, neurological treatments, and supportive care.
The Impact of Fosun at CIIE
Guo Guangchang, Chairman of Fosun International, emphasized the significance of the CIIE, stating it serves as a vital platform for international engagement and innovation. Fosun's efforts aim to turn groundbreaking medical research into tangible products that benefit patients globally. Guo expressed confidence that this platform would continue to foster opportunities, stating that healthcare innovation must address pressing clinical needs while offering hope for recovery.
Innovative Oncology Solutions
This year, Fosun introduced several cutting-edge products within oncology that emphasize a shift from treating cancer to aiming for potential cures. A standout feature was the Marie Upright Particle Therapy System, which offers a streamlined approach to particle therapy, enhancing precision for patients with tumors in various areas of the body. This innovative system supports multiple types of particle therapy, making it a game-changer in cancer treatment.
Advancements in Hematologic Oncology
Fosun continued to demonstrate its commitment to addressing hematologic disorders with Yi Kai Da, China's first CAR-T cell therapy. This therapy has played a critical role in treating lymphoma by expanding access through various insurance programs and establishing treatment centers nationwide. The introduction of brexucabtagene autoleucel injection, the company's second CAR-T product, further enhances treatment options available to patients.
Enhancing Patient Care
In addition to oncology, Fosun presented innovative supportive care medications that fill significant gaps in the local market. This includes Akynzeo, the only dual-channel antiemetic available globally, and Su Ke Xin, the first oral thrombopoietin receptor agonist in China, which targets chronic liver disease-related thrombocytopenia.
Addressing Neurological Disorders
Fosun also showcased advanced treatment options for neurological disorders, highlighting the increasing prevalence of conditions such as Parkinson's disease among younger patients. The revolutionary MRgFUS brain therapy system, which has already benefited countless patients worldwide, was on display along with Fosun's innovative drug for Parkinson's disease, Ongentys, facilitating better management of the condition.
Leveraging Digital Innovations
Fosun's commitment to advancing healthcare extends beyond traditional methods as they incorporate digital and AI technologies to enhance their medical offerings. At the CIIE, their PharmAID decision intelligence platform was highlighted as a key tool for improving decision-making processes in drug development and clinical trials. This platform reflects Fosun's strategic intent to integrate global resources in pursuit of innovation.
Training and Future Development
In a bid to bolster skills within the healthcare sector, Fosun's collaboration with hospitals to establish Da Vinci Surgical System Training Centers demonstrates their commitment to fostering education and proficiency in advanced surgical techniques. This initiative aims to ensure that healthcare professionals are well-equipped to provide high-quality care, particularly in the face of China’s evolving medical landscape.
Looking Ahead
As Fosun continues to innovate and expand, Guo Guangchang remains optimistic about the future of global healthcare. By collaborating with international partners and leveraging local insights, Fosun seeks not only to enhance its market presence but also contribute meaningfully to the realization of health initiatives, including the overarching vision of 'Healthy China 2030.'
Frequently Asked Questions
What was showcased by Fosun at CIIE?
Fosun presented innovative medical devices and pharmaceuticals focusing on oncology and neurological treatments, including the Marie Upright Particle Therapy System.
How does Fosun aim to impact healthcare?
Through innovation and global partnerships, Fosun seeks to address unmet clinical needs and improve patient outcomes across various medical fields.
What are Yi Kai Da and brexucabtagene autoleucel injection?
Yi Kai Da is China's first CAR-T cell therapy aimed at treating lymphoma, while brexucabtagene autoleucel is Fosun's second CAR-T product targeting acute lymphoblastic leukemia.
How is Fosun incorporating digital technology?
Fosun is utilizing AI-driven platforms like PharmAID to enhance drug decision-making and clinical trial predictions to refine healthcare delivery.
What is the significance of training centers established by Fosun?
These centers are designed to educate healthcare professionals in advanced surgical technologies, supporting the growth and sustainability of medical practices nationwide.
